 WEST CHESTER, Pa., Dec. 23, 2020 GLOBE NEWSWIRE -- Verrica Pharmaceuticals Inc. Verrica Nasdaq: VRCA, a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has resubmitted the New Drug Application NDA for VP-102 for the treatment of molluscum contagiosum molluscum to the U.S. Food and Drug Administration FDA. The NDA for VP-102 was resubmitted based on the outcome and final minutes of a Type A meeting with the FDA, which was conducted to obtain clarity on the Complete Response Letter CRL issued by the FDA in July 2020. 